Overcoming Resistance of Human Non-Hodgkin’s Lymphoma to CD19-CAR CTL Therapy by Celecoxib and Histone Deacetylase Inhibitors

Overcoming Resistance of Human Non-Hodgkin’s Lymphoma to CD19-CAR CTL Therapy by Celecoxib and Histone Deacetylase Inhibitors

Patients with B-cell non-Hodgkin’s lymphoma (B-NHL) who fail to respond to first-line treatment regimens or develop resistance, exhibit poor prognosis. This signifies the need to develop alternative treatment strategies. CD19-chimeric antigen receptor (CAR) T cell-redirected immunotherapy...

Full description

Bibliographic Details
Main Authors: Antoni Xavier Torres-Collado, Ali R. Jazirehi
Format: Article
Language:English
Published: MDPI AG 2018-06-01
Series:Cancers
Subjects:
chimeric antigen receptor
non-Hodgkin’s lymphoma
adoptive cell transfer
apoptosis
signal transduction
immunotherapy
resistance
B cell hematological malignancies
Celebrex
histone deacetylase inhibitor
Online Access:http://www.mdpi.com/2072-6694/10/6/200

Internet

http://www.mdpi.com/2072-6694/10/6/200

Similar Items